Rate of Treatment-Related Mortality, Most Common Causes in the Treatment of Burkitt Lymphoma
Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses the rate of treatment-related mortality and the most common causes in the treatment of Burkitt lymphoma.
Pharmacy Times interviewed Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, to discuss his SOHO 2021 conference presentation on prognostication and treatment of Burkitt lymphoma in the modern era.
During the interview, Olszewski discussed the rate of treatment-related mortality and the most common causes in the treatment of Burkitt lymphoma.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
IMS 2025: Improving Outcomes with Bispecifics in Multiple MyelomaSeptember 19th 2025
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
